Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel

British Journal of Pharmacology

Volumn 123, Issue 4, 1998, Pages 683-693

  Chappe, V ^a   Mettey, Y ^b   Vierfond, J M ^b   Hanrahan, J W ^c   Gola, M ^a   Verrier, B ^a   Becq, F ^a,d  

^a CNRS   (France)

^b Faculte de Medicine et de Pharmacie   (France)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE POITIERS   (France)

Author keywords

CFTR chloride channel; Iodide efflux; Patch clamp; Xanthine derivatives

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; CYCLIC AMP; FORSKOLIN; GLIBENCLAMIDE; IODIDE; RECOMBINANT PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; XANTHINE DERIVATIVE;

ANIMAL; ARTICLE; CHEMISTRY; CHO CELL; DRUG ANTAGONISM; DRUG POTENTIATION; HAMSTER; ION TRANSPORT; METABOLISM; PATCH CLAMP; STRUCTURE ACTIVITY RELATION;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GLYBURIDE; IODIDES; ION TRANSPORT; PATCH-CLAMP TECHNIQUES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 0031990988     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701648     Document Type: Article

References (39)

1. ARONOFK, S.C., QUINN, F.J., CARPENTER, L.S. & NOVICK, W.J. (1994). Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis; preliminary observations. J. Pediatr., 125, 992 - 997.
2. BECQ, F., FANJUL, M., MERTEN, M.D., FIGARELLA, C., HOLLANDE, E. & GOLA, M. (1993a). Possible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cells. FEBS. Letts., 327, 338 - 342.
3. BECQ, F., JENSEN, T.J., CHANG, X.-B., SAVOIA, A., ROMMENS, J.M., TSUI. L.-C., BUCHWALD, M., RIORDAN, J.R. & HANRAHAN, J.W. (1994). Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. U.S.A., 91, 9160 - 9164.
4. BECQ, F., MERTEN, M.D., VOELCKEL, M.A., GOLA, M. & FIGARELLA, C. (1993b). Characterization of cAMP dependent CFTRchloride channels in human trachéal gland cells FEBS Lett., 321, 73 - 78.
5. BECQ, F., METTEY, Y., VIERFOND, J.M., CHAPPE, V., PIN, T., HANRAHAN, J.R., RIORDAN, J.R., GOLA, M. & VERRIER, B. (1996a). Designing and synthesis of openers of the cystic fibrosis chloride channel. Ped. Pulmonol., 13, 284.
6. 2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs. J. Biol. Chem., 271, 16171 - 16179.
7. 3H]phenylxanthine. Proc. Nalt. Acad. Sci. U.S.A., 77, 5547 - 5551.
8. BRUNS, R.F., DALY, J.W. & SNYDER, S.H. (1983). Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc. Natl. Acad. Sci. U.S.A., 80, 2077 - 2080.
9. CHANG, X.-B., TABCHARANI, J.A., HOU, Y.-X., JENSEN, T.J., KARTNER, N., ALON, N., HANRAHAN, J.W. & RIORDAN, J.R. (1993). Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all ten PKA consensus phosphorylation sites. J. Biol. Chain., 268, 11304 - 11311.
10. COTTAM, H.B., SHIH, H., TEHRANI, L.R., WASSON, D.B. & CARSON, D.A. (1996). Substituted xanthines, pterinediones, and related compounds as potential antiinflammtory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α. J. Med. Chem., 39, 2 - 9.
11. CROCE, M.A., KRAMER, G.L. & GARBERS, D.L. (1979). Inhibition of alkaline phosphatase by substituted xanthines. Biochem. Pharmacol., 28, 1227 - 1231.
12. DALEMANS, W., BARBRY, P., CHAMPIGNY, G., JALLAT, S., DOTT, K., DREYER, D., CRYSTAL, R.G., PAVIRANI, A., LECOCQ, J.P. & LAZDUNSKI, M. (1991). Altered chloride ion channel kinetics associated with delta F508 cystic fibrosis mutation. Nature. 354, 526 - 528.
13. DALY, J.W., PADGETT, W.L. & SHAMIM, M.T. (1986). Analogues of caffeine and theophylline: effect of structural alterations on affnity at adenosine receptors. J. Med. Chem., 29, 1305 - 1308.
14. DRUMM, M.L., WILKINSON, D.J., SMIT, L.S., WORRELL, R.T., STRONG, T.V., FRIZZELL, R.A., DAWSON, D.C., & COLLINS, F.S. (1991). Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science, 254, 1797 - 1799.
15. EIDELMAN, O., GUAY-BRODER, C., VAN GALLEN, P.J.M., JACOBSON, K.A., FOX, C., TURNER, R.R.J., CABANTCHIK, Z.I. & POLLARD, H.B. (1992). A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. U.S.A., 89, 5562 - 5566.
16. EVONIUK, G., JACOBSON, K.A., SHAMIM, M.T., DALY, J.W. & WURTMAN, R.J. (1987). A1- and A2-selective adenosine antagonists: In vivo characterization of cardiovascular effects. J. Pharmacol. Exp. Ther., 242, 882 - 887.
17. HANRAHAN, J.W., TABCHARANI, J.A., BECQ, F., MATHEWS, C.J., AUGUSTINAS, O., JENSEN, T.J., CHANG, X.-B. & RIORDAN, J.R. (1995). Function and dysfunction of the CFTR chloride channel. In Ion Channels and Genetic Diseases, Society of General Physiologists Symposium Series, Vol.50, ed. Dawson, D.C. & Frizzell, R.A. pp. 125 - 137, Rockfeller Univ. Press.
18. HILL, R.J., OLEYNEK, J.J., HOTH, C.F., RAVIKIRON, M.A., WENG, W., WESTER, R.T., TRACEY, W.R., KNIGHT, D.R., BUCHHOLZ, R.A. & KENNEDY, S.P. (1997). Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors. J. Pharmacol. Exp. Ther., 280, 122 - 128.
19. ISLES, A., SPINO, M., TABACHNIK, E., LEVISON, H., THIESSEN, J. & MACLEOD, S. (1983). Theophylline disposition in cystic fibrosis. Am. Rev. Respir. Dis., 127, 417 - 421.
20. JACOBSON, K.A., GALLO-RODRIGUEZ, X., MELMAN, N., MAILLARD, M., VAN, BERGEN, A., VAN GALLEN, P.J.M. & KARTON, Y. (1993). Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J. Med. Chem., 36, 1333 - 1342.
21. JACOBSON, K.A., GUAY-BRODER, C., VAN GALLEN, P.J.M., GALLO-RODRIGUEZ, C., MELMAN, N., MAILLARD, M., JACOBSON, M.A., EIDELMAN, O. & POLLARD, H.B. (1995). Stimulation by alkylxanthine of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. Biochemistry, 34, 9088 - 9094.
22. KATZ, U. & NAGEL, W. (1995). Effect of cyclic AMP and theophylline on chloride conductance across toad skin. J. Physiol., 489, 105 - 114.
23. KNOPPERT, D.C., SPINO, M., BECK, R., THIESSEN, J.J. & MACLEOD, S. (1988). Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin. Pharmacol. Ther., 44, 254 - 264.
24. KOCH, M.C., STEINMEYER, K., LORENZ, C., RICKER, K., WOLF, F., OTTO, M., ZOLL, B., LEHMANN-HORN, F., GRZESCHIK, K.H. & JENTSCH, T.J. (1992). The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 257, 797 - 800.
25. LARSEN, G.L., BARRON, R.J., LANDAY, R.A. & COTTON, E.K. (1980). Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effects on pulmonary function. Am. J. Dis. Child., 134, 1143 - 1148.
26. LOGAN, J., HIESTAND, D., HUANG, Z., MUCCIO, D., HALEY, B. & SORSCHER, E.J. (1993). 3-Isobutyl-1-methylxanthine (IBMX) blocks binding of ATP analogs to the CFTR first nucleotide binding domain (NBD-1). FASEB J., 7, A426.
27. MIYAMOTO, K.-I., SAKAI, R., KURITA, M., OHMAE, S., SANAE, F., SAWANISHI, H., HASEGAWA, T. & TAKAGI, K. (1995). Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes. Biol. Pharm. Bull., 18, 431 - 434.
28. MIYAMOTO, K.-I., YAMAMOTO, Y., KURITA, M., SAKAI, R., KONNO, K., SANAE, F., OHSHIMA, T., TAKAGI, K., HASEGAWA, T., IWASAKI, N., KAKIUCHI, M. & KATO, H. (1993). Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position. J. Med. Chem., 36, 1380 - 1386.
29. PAN, S.-H., CANAFAX, D.M., LE, C.T., CIPOLLE, R.J., UDEN, D.L. & WARWICK, W. (1989). Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. Pediatr. Pulmonol., 6, 172 - 179.
30. PERSSON, C.G.A. (1986). Development of safer xanthine drugs for treatment of obstructive airway disease. J. Allergy Clin. Immunol., 78, 817 - 824.
31. RIORDAN, J.R., ROMMENS, J.M., KEREM, B.-S., ALON, N., ROZMAHEL, R., GRZELCZAK, Z., ZIELENSKI, J., LOK, S., PLAVSIC, N, CHOU, J.-L., DRUMM, M.L., IANNUZZI, M.C., COLLINS, F.S. & TSUI, L.-C. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245, 1066 - 1072.
32. SAKAI, R., KONNO, K., YAMAMOTO, Y., SANAE, F., TAKAGI, K., HASEGAWA, T., IWASAKI, N., KAKIUCHI, M., KATO, H. & MIYAMOTO, K.-I. (1992). Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J. Med. Chem., 35, 4039 - 4044.
33. SIMASKO, S.M. & YAN, S. (1993). 3-Isobutyl-1-methylxanthine inhibits sustained calcium current independently of cyclic AMP in neuronal and endocrine cells. Molec. Pharmacol., 44, 622 - 627.
34. SNYDER, S.H., KATIMS, J.J., ANNAU, Z., BRUNS, R.F. & DALY, J.W. (1981). Adenosine receptors and behaviour actions of methylxanthines. Proc. Natl. Acad. Sci. U.S.A., 78, 3260 - 3264.
35. STEINMEYER, K., SCHWAPPACH, B., BENS, M., VANDEWALLE, A. & JENTSCH, T.J. (1995). Cloning and functional expression of rat CLC-5, a chloride channel related to kidney disease. J. Biol. Chem., 270, 31172 - 31177.
36. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature. 352, 628 - 631.
37. TSUI, L.-C. & BUCHWALD, M. (1991). Biochemical and molecular genetics of cystic fibrosis. Adv. Human Genetic., 20, 153 - 266.
38. UKENA, D., SCHUDT, C. & SYBRECHT, G. (1993). Adenosine receptor blocking xanthines as inhibitors of phosphodiesterase isozymes. Biochem. Pharmacol., 45, 847 - 851.
39. in. Pflügers Arch.-Eur. J. Physiol., 430, 420-428.